Lake Street raised the firm’s price target on Cellebrite (CLBT) to $23 from $22 and keeps a Buy rating on the shares. The firm was “pleased to see Cellebrite get back on track” following what it calls out as “two consecutive quarters of disappointment.” The firm, which raised its 2025 estimates, tells investors that the strength in U.S. state and local and LATAM have it “feeling more confident the business is back on the right track.”
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLBT:
- Cellebrite price target raised to $25 from $24 at BofA
- Cellebrite price target raised to $24 from $23 at JPMorgan
- Cellebrite DI: Strong Financial Performance and Promising Growth Prospects Drive Buy Rating
- Cellebrite DI Positioned for Growth: Buy Rating Affirmed Amid Federal Demand Recovery and Strategic Alignments
- Cellebrite Reports Strong Q3 2025 Financial Results